Drugs / SER-287
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02618187 | Jan 2016 → Dec 2017 | ulcerative colitis | Seres Therapeutics, Inc. | Completed | Mixed |
| Phase 21 trial | ||||||
| Phase 2 | NCT03759041 | Dec 2018 → May 2021 | ulcerative colitis | Seres Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02618187 ↗ |
| Modality | Other / unclassified | “A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.” PMID 32763240 ↗ Aug 2020 |
| Route | Oral | “8 weeks of oral SER-287 or placebo” PMID 32763240 ↗ Aug 2020 |